RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...

RBC Capital analyst Luca Issi reiterated a Buy rating on Korro Bio (KRRO – Research Report) yesterday and set a price target of $95.00. The ...

Matador Technologies Inc. ('Matador” or the 'Company”) (TSXV: MATA) is pleased to announce that it has received approval to list its common shares on the OTC Markets under the ticker symbol ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

Over the 50 years since UnitedHealth was founded, Richard T. Burke (81) has given few interviews. Now he has given an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Featured here, the Cash Flow Statement for Korro Bio Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the ...